文献速递骨质疏松与代谢性骨病

将骨折风险评估工具FRAX再利用为女性肌少症风险筛查工具

Repurposing a fracture risk calculator (FRAX) as a screening tool for women at risk for sarcopenia.
PubMed 文献 · Osteoporos Int · 2020-03-17

在Geelong骨质疏松研究中,对354名40-90岁女性计算FRAX概率,十年后用DXA和握力按EWGSOP2评估肌少症。无BMD的FRAX预测肌少症AUROC达0.90(髋部骨折)和0.88(主要骨质疏松性骨折),提示其可能作为肌少症筛查工具。

要点

  • 无BMD的FRAX预测肌少症敏感性高、特异性合理。
  • 无BMD的髋部骨折FRAX的AUROC为0.90,最佳阈值0.9。
  • 计算FRAX时加入BMD未改善对肌少症的预测性能。

核心结论

  • 无BMD的FRAX概率可能以高敏感性和合理特异性预测肌少症。
  • FRAX临床危险因素无需设备即可获取,有潜力用于筛查肌少症风险个体。

研究设计与样本

  • 纵向研究,纳入Geelong骨质疏松研究中354名40-90岁女性。
  • 基线计算FRAX(澳大利亚)概率,十年后按EWGSOP2评估肌少症。

主要发现

  • 随访时11名(3.1%)女性被确定为肌少症。
  • 无BMD时,髋部骨折FRAX的AUROC为0.90,主要骨质疏松性骨折FRAX的AUROC为0.88。
  • 髋部骨折FRAX最佳阈值为0.9(敏感性90.9%,特异性62.4%),主要骨质疏松性骨折FRAX最佳阈值为5.3(敏感性81.8%,特异性71.7%)。
  • 计算FRAX时加入BMD未改善对肌少症的预测性能。

关键数值与推荐

  • 肌少症评估采用DXA-derived低四肢 lean mass(ALM/height² < 5.5 kg/m²)和低握力(HGS < 16 kg),依据EWGSOP2。
  • 基线无BMD的髋部骨折FRAX中位数(IQR)为0.4(0.1-1.3),主要骨质疏松性骨折FRAX为2.4(1.2-5.2)。
  • 基线有BMD的髋部骨折FRAX中位数(IQR)为0.2(0.0-0.7),主要骨质疏松性骨折FRAX为2.1(1.1-4.4)。

临床怎么用

  • 可考虑使用无BMD的FRAX概率识别肌少症风险女性,尤其髋部骨折FRAX阈值0.9时敏感性高。
  • FRAX临床危险因素无需设备,便于社区或初级保健筛查。

局限性

  • 肌少症病例数较少(11例,3.1%)。
  • 本研究为初步证据,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Osteoporosis and sarcopenia share risk profiles, so we tested a fracture risk assessment tool (FRAX) as a screening tool for sarcopenia. FRAX probabilities without bone mineral density predicted sarcopenia with high sensitivity and reasonable specificity. There is potential to use this FRAX as a screening tool for sarcopenia. PURPOSE: There is a need for simple screening tools for sarcopenia. As osteoporosis and sarcopenia share risk profiles, we tested the performance of a fracture risk assessment tool for discriminating individuals at risk for sarcopenia. METHODS: In this longitudinal study, FRAX (Australia) probabilities were calculated for 354 women (ages 40-90 years) in the Geelong Osteoporosis Study. Sarcopenia was assessed a decade later using DXA-derived low appendicular lean mass (Lunar; ALM/height2 < 5.5 kg/m2) and low handgrip strength (Jamar; HGS < 16 kg), according to EWGSOP2. We determined FRAX probabilities (%) for hip fracture (HF-FRAX) and major osteoporotic fracture (MOF-FRAX), with and without BMD. Area under the receiver operator characteristic (AUROC) curves quantified the performance of FRAX for predicting sarcopenia. RESULTS: Baseline median (IQR) values for HF-FRAX without BMD were 0.4 (0.1-1.3) and for MOF-FRAX without BMD, 2.4 (1.2-5.2); comparable figures for HF-FRAX with BMD were 0.2 (0.0-0.7) and for MOF-FRAX with BMD, 2.1 (1.1-4.4). At follow-up, sarcopenia was identified for 11 (3.1%) women. When FRAX was calculated without BMD, the AUROC was 0.90 for HF-FRAX and 0.88 for MOF-FRAX. Optimal thresholds were 0.9 for HF-FRAX (sensitivity 90.9%, specificity 62.4%) and 5.3 for MOF-FRAX (sensitivity 81.8%, specificity 71.7%). Calculating FRAX with BMD did not improve the predictive performance of FRAX for sarcopenia. CONCLUSION: Here we provide preliminary evidence to suggest that FRAX probabilities without BMD might predict sarcopenia with high sensitivity and reasonable specificity. Given that FRAX clinical risk factors are identified without equipment, there is potential to use this or a modified version of the FRAX tool to screen for individuals at risk of sarcopenia.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Pasco JA, Mohebbi M, Tembo MC, et al. Repurposing a fracture risk calculator (FRAX) as a screening tool for women at risk for sarcopenia. Osteoporos Int. 2020. PMID: 32185435. doi:10.1007/s00198-020-05376-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。